CGT1145 — IND submission
2026
We plan to submit an IND for this program in 2026.Source filing
COGT biotech catalysts & pipeline
COGENT BIOSCIENCES INC · Data as of 2026-09-08
Upcoming catalysts
CGT1815 — IND submission
2026
We plan submit an IND for this program in 2026.Source filing
CGT4859 — Initial data
2026
We expect to share clinical data from our Phase 1 study in 2026.Source filing
JAK2 — IND submission
2026
We plan to submit an IND for this program in 2026.Source filing
KRAS — IND submission
2026
We plan to submit an IND for this program in 2026.Source filing
avapritinib — Initial data
Late 2026
Announced completion of enrollment in the "avapritinib switch" SUMMIT extension trial with preliminary results expected by end of 2026.Source filing
bezuclastinib — PDUFA
Nov 30
Potential FDA approval of bezuclastinib in GIST – PDUFA date of November 30, 2026Source filing
bezuclastinib — PDUFA
Dec 30
Potential FDA approval of bezuclastinib in NonAdvSM – PDUFA date of December 30, 2026Source filing